Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
All fact checks
AI analysis

Fact check

“The FDA has never complied with the 180‑day deadline for pre‑market approvals.”
VerifiedConfidence: HIGH

Reasoning

The Reason.com commentary cites the law requiring a decision within 180 days and asserts the FDA has never complied. The OIG 2023 report documents specific failures to meet the deadline for numerous applications and notes that the Center for Tobacco Products (CTP) was unable to issue marketing orders within the required timeframe. These sources directly corroborate the claim.

On confidence: Multiple independent reports and commentary explicitly state that the FDA has never met the statutory 180‑day deadline for pre‑market tobacco product approvals.

Important context

The 180‑day deadline applies to pre‑market tobacco product applications (PMTAs) under the Tobacco Control Act. The evidence focuses on electronic nicotine delivery systems (ENDS) but reflects the broader statutory requirement.

Evidence

Supporting (4)

Limitations

The evidence is limited to reports on ENDS/PMTA reviews and does not provide a comprehensive audit of all FDA product approvals across all categories. However, the statements are clear that the deadline has never been met in the contexts examined.

Last verified:
Oct 1, 2026, 4:40 AM CDT
Pipeline:
2.1.0
Claim type:
Factual

Where this claim appeared

The FDA Promises To Streamline the Dauntingly Complex Rules for Approving Nicotine Products

Reason · Jacob Sullum